Asset
Niraparib
Zai Lab Limited American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03516084 | phase3 | terminated | 2018-08-20 | 2020-02-21 | Zai Lab (Shanghai) Co., Ltd. | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer |
| NCT03709316 | phase3 | unknown | 2018-06-30 | 2022-01-29 | Zai Lab (Shanghai) Co., Ltd. | A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer |
| NCT03705156 | phase3 | unknown | 2017-06-08 | 2020-02-01 | Zai Lab (Shanghai) Co., Ltd. | Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient |
| NCT03551171 | phase1 | completed | 2017-12-19 | 2018-05-03 | Zai Lab (Shanghai) Co., Ltd. | The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer |
FDA applications (0)
This company has no applications containing this asset.